Path BioAnalytics
MCC’s investment in Path BioAnalytics (PBA) supported the creation of a new biobank that houses pancreatitis patient cell specimens, matching genetic and clinical data from people who have been diagnosed with pancreatitis or are at high risk of developing pancreatitis. The biobank provides a valuable resource for basic, translational and advanced research that will lead to better understanding, diagnosis and treatment of pancreatitis.
PBA utilizes a precision medicine-based approach to drug development, leveraging the company’s proprietary organoid and artificial intelligence technologies. Combining these advanced technologies into a streamlined platform, PBA is able to incorporate patient-specific in vitro data into the drug development process prior to starting clinical trials, significantly reducing time and cost. PBA’s patient-centric approach allows the company to de-risk R&D decisions, improve the efficiency of drug testing using relevant primary cells, and ultimately, produce more effective medicines for targeted patient populations.
“Mission Cure Capital’ funding, industry relationships and program support will help ensure PBA is successful in bringing effective therapies to pancreatitis patients”
- John Mellnik, PBA President & CEO